Dabigatran etexilate-induced alveolar hemorrhage
Kenichiro Kudoa Yasushi Tanimotoa Akiko Hisamotoa Eiki Ichiharaa Mitsune Tanimotob Katsuyuki Kiuraa
aDepartment of Allergy and Respiratory Medicine, Okayama University Hospital
bDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
A 74-year-old woman had taken dabigatran etexilate for chronic atrial fibrillation since March 2011. She visited a local hospital, presenting with bloody sputum, cough, and macrohematuria in June 2011. A chest radiograph and computed tomography scan revealed diffuse ground-glass opacities and consolidation in the middle and bilateral lower lobes. She was referred to our hospital 3 days after the symptoms appeared. Bronchoalveolar lavage fluid (BALF) showed bloody fluid. The clinical symptoms and radiological features rapidly improved after dabigatran etexilate was discontinued. As far as we searched, this is the first report of pulmonary alveolar hemorrhage resulting from dabigatran etexilate.
Dabigatran etexilate Alveolar hemorrhage Bronchoalveolar lavage
Received 19 Aug 2011 / Accepted 15 Nov 2011
AJRS, 1(3): 247-250, 2012